Aqilion
Business Services · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
C/o Hetch Ab Redaregatan 48, Helsingborg...Phone Number
+46 702614575Website
www.aqilion.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aqilion
Aqilion is a Swedish life science company focused on developing innovative treatments for chronic inflammatory diseases and dysfunctional immune reactions. The company identifies and refines early drug innovation ideas into commercially viable projects based on solid scientific research. Aqilion operates primarily in the early phases of drug discovery, collaborating with partners to advance its development programs. Their mission is to improve patient quality of life through novel therapeutic solutions in areas with significant unmet medical needs.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aqilion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Aqilion launches new products
Congratulate Masked Content for being promoted to Masked Content at Aqilion
Check if Aqilion has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Aqilion recently announced quarterly report
Aqilion, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Aqilion has new funding data
Website visits: Recent activity has been detected on your website
Check out if Aqilion is spiking on competitors!
Click to see if Aqilion had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Aqilion as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Aqilion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aqilion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aqilion.
Aqilion Tech Stack
A closer look at the technologies used by Aqilion
Most Recent Scoops
Left Company
Executive Move
As previously announced, Gustaf Albèrt, Chief Financial Officer, has recently left the organization.
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
New Hire
Executive Move
Aqilion News & Media
Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna
AQILION AB (publ) is developing the anti-inflammatory drug candidate AQ312 for the treatment of ulcerative colitis, and presents new results from the Aqilion preclinical development program at the United European Gastroenterology (UEG) Week in Vienna. Wayne Russell, Senior Director Translational Biology and Innovation, presents new preclinical data describing the drug candidate AQ312 in several gastrointestinal disease models. The presentation will take place during UEG Week 2024 in Vienna on OcAqilion regains rights to TAK1 program
AQILION AB (publ) announces that Aqilion and Merck have decided to terminate the joint development of the TAK1 program. Data generated in the course of the collaboration have altered the risk-benefit profile within the intended indications. Merck will return all rights according to the licensing and collaboration agreement that was entered between the two parties in February 2023. Aqilion will ensure that all data and materials will be transferred to the company and will thereafterResolutions from AQILION AB (publ) Annual General Meeting 2024
Helsingborg, June 10, 2024 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance with the proposals presented. For more detailed information on the content of the resolutions, please see the full notice to the Annual General Meeting, which is available on Aqilion's website, www.aqilion.com Adoption of income statements and balance sheets The Annual General Meeting approved the income statement and balance sheet included in the annual reportAqilion to present results at scientific events
AQILION AB (publ) will present updates on the Company's progress and scientific results at two different scientific conferences in May. The presentations will cover the pipeline programs AQ280 for the treatment of eosinophilic esophagitis and AQ312 for the treatment of ulcerative colitis. Johan Lund, CSO, will present Aqilion's pipeline with a special focus on the pipeline programs AQ280 and AQ312 at the 20th Annual Conference of International Drug Discovery and Science technology (IDDST) in Osa
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Aqilion
Sign Up For FreeTo access detailed company insights
Aqilion is a Swedish life science company focused on developing innovative treatments for chronic inflammatory diseases and dysfunctional immune reactions. The company identifies and refines early drug innovation ideas into commercially viable projects based on solid scientific research. Aqilion operates primarily in the early phases of drug discov... Read More
